256 related articles for article (PubMed ID: 25268193)
41. The in vitro effects of hepatoblastoma cells on the growth and differentiation of blasts in transient abnormal myelopoiesis associated with Down syndrome.
Miyauchi J; Kawaguchi H
Leuk Res; 2021 Jun; 105():106570. PubMed ID: 33838549
[TBL] [Abstract][Full Text] [Related]
42. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
43. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
[TBL] [Abstract][Full Text] [Related]
44. Evolution of myeloid leukemia in children with Down syndrome.
Saida S
Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
[TBL] [Abstract][Full Text] [Related]
45. The hematopoietic microenvironment of the fetal liver and transient abnormal myelopoiesis associated with Down syndrome: A review.
Miyauchi J
Crit Rev Oncol Hematol; 2024 Jul; 199():104382. PubMed ID: 38723838
[TBL] [Abstract][Full Text] [Related]
46. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Druschel CM; Sandoval C
Blood; 2007 Sep; 110(6):2128-31. PubMed ID: 17576817
[TBL] [Abstract][Full Text] [Related]
47. A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21.
Stepensky P; Brooks R; Waldman E; Revel-Vilk S; Izraeli S; Resnick I; Weintraub M
Pediatr Blood Cancer; 2010 Jul; 54(7):1048-9. PubMed ID: 20108342
[TBL] [Abstract][Full Text] [Related]
48. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
[TBL] [Abstract][Full Text] [Related]
49. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
[TBL] [Abstract][Full Text] [Related]
50. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome.
Zipursky A; Brown E; Christensen H; Sutherland R; Doyle J
Semin Perinatol; 1997 Feb; 21(1):97-101. PubMed ID: 9190039
[TBL] [Abstract][Full Text] [Related]
51. [The role of GATA1 mutation in acute megakaryocytic leukemia].
Ito E
Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
[No Abstract] [Full Text] [Related]
52. Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.
Inaba H; Londero M; Maurer SH; Onciu M; Ge Y; Taub JW; Rubnitz JE; Raimondi SC
J Clin Oncol; 2011 Mar; 29(9):e230-3. PubMed ID: 21205752
[No Abstract] [Full Text] [Related]
53. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.
Heald B; Hilden JM; Zbuk K; Norton A; Vyas P; Theil KS; Eng C
Nat Clin Pract Oncol; 2007 Jul; 4(7):433-8. PubMed ID: 17597708
[TBL] [Abstract][Full Text] [Related]
54. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
[TBL] [Abstract][Full Text] [Related]
55. Haematopoietic development and leukaemia in Down syndrome.
Roberts I; Izraeli S
Br J Haematol; 2014 Dec; 167(5):587-99. PubMed ID: 25155832
[TBL] [Abstract][Full Text] [Related]
56. Generation of 2 isogenic clones from a patient with Trisomy 21 and a GATA1 mutation.
Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
Stem Cell Res; 2023 Jun; 69():103098. PubMed ID: 37084616
[TBL] [Abstract][Full Text] [Related]
57. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
[TBL] [Abstract][Full Text] [Related]
58. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
Terui K; Toki T; Taga T; Iwamoto S; Miyamura T; Hasegawa D; Moritake H; Hama A; Nakashima K; Kanezaki R; Kudo K; Saito AM; Horibe K; Adachi S; Tomizawa D; Ito E
Genes Chromosomes Cancer; 2020 Mar; 59(3):160-167. PubMed ID: 31606922
[TBL] [Abstract][Full Text] [Related]
59. Erythrophagocytic megakaryoblasts in acute megakaryoblastic leukaemia.
Wong KF; Yu PH
Br J Haematol; 2010 Mar; 148(5):672. PubMed ID: 19663828
[No Abstract] [Full Text] [Related]
60. Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome.
Xu G; Kanezaki R; Toki T; Watanabe S; Takahashi Y; Terui K; Kitabayashi I; Ito E
Leukemia; 2006 Jun; 20(6):1002-8. PubMed ID: 16628190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]